Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation

Table 1 Hepatocellular carcinoma patients’ pre-transplant α-fetoprotein level, outcome, and biological features according to some recent studies

Ref.	No. of patients	Static AFP cut-off (mg/L)	Dynamic AFP	Outcome for increasing AFP ranges	Pvalue	Other biological features
Berry et al[31] (2013)	8659	≤ 15, 16-66, 66-320, > 320	-	6 yr OS: from 70% to 60%, 57%, 51%	-	-
Toso et al[26] (2011)	6478	≤ 100, 100-500, > 500	-	3 yr OS: from 71% to 60%, 51%	< 0.001	-
Mailey et al[32] (2011)	2253	≤ 20, > 400	-	4 yr OS: from 76% to 54%	< 0.001	-
Duvoux et al[20] (2012)	1033	≤ 100, 100-1000, > 1000	-	5 yr OS: from 68% to 51%, 39%	< 0.001	VI, poor differentiation
Todo et al[30] (2007)	653	≤ 200, > 1000	-	5 yr OS: from 73% to 34%	< 0.001	-
Fujiki et al[41] (2009)	144	≤ 200, > 800	-	5 yr RFS: from 90% to 40%	0.003	VI, poor differentiation
Sotiropoulos et al[12]	100	≤ 20, 20-200, 200-1000, > 1000	-	5 yr RFS: from 97% to 60%, 57%, 51%	0.0003	-
Hameed et al[45]	211	≤ 1000, > 1000	-	5- yr RFS: from 80.3% to 52.7%	0.025	VI
Kondili et al[46]	32	-	grate increasing, low increasing	In 5 Patents with recurrence AFP increased at a greater magnitude than in 27 without recurrence	-	-
Han et al[28]	48	-	≤ 50 mg/L per month, > 50 mg/L per month	1 yr RFS: from 90% to 40%	< 0.001	VI
Vibert et al[29]	153	-	≤ 15 mg/L per month, > 15 mg/L per month	5 yr RFS: from 76% to 54%	0.01	VI
Merani et al[47]	6817	-	Stable, ≥ 400, downstaged to < 400	ITT survival: from 81% to 48%	< 0.001	-

OS: Overall survival rate; RFS: Recurrence-free survival rate; ITT: Intention-to-treat; VI: Vascular invasion.